How Investors May Respond To Teva (TEVA) Advancing TEV ‘325 In Biologics For Inflammatory Diseases

Simply Wall St.03-26

Biolojic Design recently announced that TEV ‘325, a multibody targeting IL-13 and TSLP for TH2-driven inflammatory diseases, achieved a preclinical milestone in its collaboration with Teva, triggering...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622831337?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/308047-main-header/1585187365850","is_english":true,"pubTime":"2026-03-26 14:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622831337","market":"us","top_or_hot":-1,"title":"How Investors May Respond To Teva (TEVA) Advancing TEV ‘325 In Biologics For Inflammatory Diseases","media":"Simply Wall St.","content":"<div>\n<p>Biolojic Design recently announced that TEV ‘325, a multibody targeting IL-13 and TSLP for TH2-driven inflammatory diseases, achieved a preclinical milestone in its collaboration with Teva, triggering...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-teva/teva-pharmaceutical-industries/news/how-investors-may-respond-to-teva-teva-advancing-tev-325-in\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How Investors May Respond To Teva (TEVA) Advancing TEV ‘325 In Biologics For Inflammatory Diseases</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow Investors May Respond To Teva (TEVA) Advancing TEV ‘325 In Biologics For Inflammatory Diseases\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-26 14:11 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-teva/teva-pharmaceutical-industries/news/how-investors-may-respond-to-teva-teva-advancing-tev-325-in><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biolojic Design recently announced that TEV ‘325, a multibody targeting IL-13 and TSLP for TH2-driven inflammatory diseases, achieved a preclinical milestone in its collaboration with Teva, triggering...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-teva/teva-pharmaceutical-industries/news/how-investors-may-respond-to-teva-teva-advancing-tev-325-in\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4559","symbol_name":"巴菲特持仓","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-teva/teva-pharmaceutical-industries/news/how-investors-may-respond-to-teva-teva-advancing-tev-325-in","article_id":"2622831337","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/308047-main-header/1585187365850"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-teva/teva-pharmaceutical-industries/news/how-investors-may-respond-to-teva-teva-advancing-tev-325-in","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2622831337","pubTimestamp":1774505503,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Biolojic Design recently announced that TEV ‘325, a multibody targeting IL-13 and TSLP for TH2-driven inflammatory diseases, achieved a preclinical milestone in its collaboration with Teva, triggering milestone payments and confirming Teva’s exclusive global development and commercialization rights.\nThis milestone underscores Teva’s progress in innovative biologics, adding scientific and commercial depth to its inflammatory disease pipeline alongside its established generics and branded...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4559":"巴菲特持仓","BK4596":"哈里斯概念","BK4007":"制药","BK4566":"资本集团","BK4584":"避孕概念","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","BK4211":"区域性银行","TEVA":"梯瓦制药","BK4588":"碎股","BK4585":"ETF&股票定投概念","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","BK4557":"大麻股","ISBC":"投资者银行"},"translate_title":"投资者对梯瓦(TEVA)在炎症性疾病生物制剂领域推进TEV'325有何反应","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ISBC":1.5,"TEVA":1.5},"content_text":"Biolojic Design recently announced that TEV ‘325, a multibody targeting IL-13 and TSLP for TH2-driven inflammatory diseases, achieved a preclinical milestone in its collaboration with Teva, triggering milestone payments and confirming Teva’s exclusive global development and commercialization rights. This milestone underscores Teva’s progress in innovative biologics, adding scientific and commercial depth to its inflammatory disease pipeline alongside its established generics and branded therapies. We’ll now examine how progress on TEV ‘325, as a novel biologic for TH2-driven diseases, may influence Teva’s broader investment narrative. Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 26 best rare earth metal stocks of the very few that mine this essential strategic resource.AdvertisementTeva Pharmaceutical Industries Investment Narrative RecapTo be comfortable owning Teva today, you need to believe the turnaround from loss to US$1.41 billion in 2025 profit can be sustained while the company manages debt and pricing pressure on key brands. The TEV ‘325 preclinical milestone is encouraging for Teva’s longer term immunology ambitions, but it does not materially change the near term focus on execution in branded neurology, biosimilars, and ongoing deleveraging, which remain the key catalyst and risk drivers. The most relevant recent announcement alongside TEV ‘325 is the positive long term RELIEVE UCCD LTE data for duvakitug in ulcerative colitis and Crohn’s disease, which reinforces Teva’s push into higher value immunology and inflammatory diseases. Together, duvakitug progress and TEV ‘325’s advancement highlight how newer biologics could gradually rebalance Teva’s reliance on generics and a small group of flagship branded therapies, adding another layer of optionality around future growth catalysts. Yet, while the innovation story is building, investors should still be aware of the concentration risk around AUSTEDO and the looming IRA impact on... Read the full narrative on Teva Pharmaceutical Industries (it's free!)Teva Pharmaceutical Industries' narrative projects $17.8 billion revenue and $1.5 billion earnings by 2028.Uncover how Teva Pharmaceutical Industries' forecasts yield a $38.14 fair value, a 29% upside to its current price.Exploring Other PerspectivesTEVA 1-Year Stock Price Chart By contrast, the most bearish analysts were assuming only about 1 percent annual revenue growth and earnings of roughly US$1.6 billion by 2028, which shows how differently you and they might weigh new assets like TEV ‘325 against concerns about pipeline execution and cost savings targets.Explore 4 other fair value estimates on Teva Pharmaceutical Industries - why the stock might be worth over 2x more than the current price!Decide For YourselfDon't just follow the ticker - dig into the data and build a conviction that's truly your own.A great starting point for your Teva Pharmaceutical Industries research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.Our free Teva Pharmaceutical Industries research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Teva Pharmaceutical Industries' overall financial health at a glance.Looking For Alternative Opportunities?Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Teva Pharmaceutical Industries might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622831337","isCrawlerRequest":true}